Skip to main content

Table 3 Results of the multivariable Cox model for overall survival

From: Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis

Variable

Risk category

Beta

HR

95% CI

p-value

Sex

Male/female

0.00

1.00

(0.86-1.15)

0.950

Age

>65 years/<65 years

−0.03

0.97

(0.83-1.13)

0.680

Site of primary tumour

Rectum/colon

0.11

1.12

(0.97-1.29)

0.130

Primarily metastatic

M1/M0

0.29

1.34

(1.14-1.56)

<0.001

Number of metastatic sites

2/1

0.38

1.47

(1.26-1.71)

<0.001

 

3 and more/1

0.66

1.94

(1.57-2.39)

<0.001

Chemotherapy regimen

XELOX/FOLFOX

−0.10

0.91

(0.76-1.09)

0.290